AC Immune SA (NASDAQ:ACIU) and Agenus Inc. (NASDAQ:AGEN) compete against each other in the Biotechnology sector. We will compare them and contrast their risk, analyst recommendations, institutional ownership, profitability, dividends, earnings and valuation.

Earnings and Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AC Immune SA	N/A	0.00	N/A	-0.54	0.00
Agenus Inc.	38.69M	12.23	147.18M	-1.40	0.00

Table 1 highlights AC Immune SA and Agenus Inc.’s gross revenue, earnings per share and valuation.

Profitability

Table 2 represents AC Immune SA (NASDAQ:ACIU) and Agenus Inc. (NASDAQ:AGEN)’s return on assets, net margins and return on equity.

	Net Margins	Return on Equity	Return on Assets
AC Immune SA	0.00%	-25.2%	-22.4%
Agenus Inc.	-380.41%	136.2%	-110.7%

Liquidity

The Current Ratio and Quick Ratio of AC Immune SA are 19.2 and 19.2 respectively. Its competitor Agenus Inc.’s Current Ratio is 1.2 and its Quick Ratio is 1.2. AC Immune SA can pay off short and long-term obligations better than Agenus Inc.

Insider and Institutional Ownership

The shares of both AC Immune SA and Agenus Inc. are owned by institutional investors at 30.3% and 32.4% respectively. 51.48% are AC Immune SA’s share held by insiders. Competitively, Agenus Inc. has 0.1% of it’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
AC Immune SA	-1.53%	24.15%	37.22%	11.28%	-8.75%	-14.45%
Agenus Inc.	9.13%	27.05%	32.83%	-9.62%	-27.35%	-19.33%

For the past year AC Immune SA has stronger performance than Agenus Inc.

Summary

AC Immune SA beats Agenus Inc. on 6 of the 9 factors.

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms generates antibodies and small molecules that selectively bind to misfolded proteins to address neurodegenerative indications, such as AlzheimerÂ’s (AD), ParkinsonÂ’s, down syndrome, and glaucoma diseases. The companyÂ’s lead product candidate is crenezumab, a humanized, monoclonal, and conformation-specific anti-Abeta antibody, which is in Phase 3 clinical studies. It also engages in developing ACI-24, a vaccine candidate that is in a combined Phase 1/2a clinical study for AD; and ACI-35, a vaccine candidate against phosphorylated pathological tau and is currently in Phase 1b clinical testing in patients with mild to moderate AD. In addition, the company develops PET ligands that are tracers to target tau and alpha-synuclein aggregates. It has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Piramal Imaging; and Biogen International GmbH. AC Immune SA was founded in 2003 and is headquartered in Lausanne, Switzerland.

Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the bodyÂ’s immune system for patients suffering with cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. It is also developing checkpoint modulating antibody candidates targeting GITR, OX40, TIM-3, and LAG-3. In addition, the company develops vaccine programs, such as Prophage cancer vaccine candidate; AutoSynVax, a synthetic cancer vaccine program targeting the neo-epitope landscape in cancer patients; and PhosPhoSynVax, a vaccine candidate designed to induce immunity against a novel class of tumor specific neo-epitopes. Further, Agenus Inc. develops QS-21 Stimulon, a saponin-based vaccine adjuvant that has completed Phase III clinical trials for the treatment of malaria and shingles. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.